The ongoing legal battle over Moderna’s COVID-19 vaccine patents has intensified, as influential organizations such as the American Intellectual Property Law Association (AIPLA) and the National Association of Manufacturers (NAM) advocate for the biotech giant. They have urged the Federal Circuit to reverse a lower court’s decision that holds Moderna accountable for a multibillion-dollar patent infringement lawsuit, rather than the U.S. government. This legal confrontation emphasizes the intricate interplay between private innovation and public necessity in the wake of the pandemic.
In the initial ruling, a district court found that Moderna could not claim government immunity in the dispute with Arbutus Biopharma and Genevant Sciences over the mRNA technology employed in its vaccine. AIPLA and NAM argue that such decisions could deter private companies from engaging in critical government-supported research and development. Their brief emphasizes the potential chilling effect on the nation’s ability to respond swiftly to public health emergencies. Detailed reporting on this matter can be [found here](https://www.law360.com/ip/articles/2486551?utm_source=rss&utm_medium=rss&utm_campaign=section).
The basis for Moderna’s defense lies in invoking a provision under 28 U.S.C. § 1498, which protects contractors from patent liability when producing goods for the U.S. government. This statute has historically been instrumental in securing partnerships between the government and private sector innovators. Yet, the district court’s interpretation challenges this established legal principle. As noted in an analysis by Bloomberg Law, the outcome of this appeal holds significant implications for the legal landscape surrounding biopharmaceutical patents.
The involvement of AIPLA and NAM underscores the broader industry concern regarding the potential precedent established by the court’s decision. Reuters highlighted that these organizations believe the ruling could undermine collaborations essential for national priorities, from healthcare to defense.
As this case progresses through the courts, it represents a pivotal moment in assessing the rights and responsibilities of innovation during crises. Stakeholders from all facets of the industry are closely observing, understanding that the resolution may shape the future of patent law and government-private sector collaborations in the United States.